EMJ Oncology 14 [Supplement 1] . 2026

In this issue

The European Society for Medical Oncology (ESMO) Congress 2025 featured important discussions on optimising treatment strategies for patients with ER+/HER2- advanced/metastatic breast cancer. In this symposium, leading oncologists explored evolving second-line and beyond approaches following CDK4/6 inhibitor therapy, emphasising biomarker-driven decisions and the critical role of ESR1 mutation testing in guiding therapeutic choices.